Slide 1: Myriad Genetics Fiscal Third-Quarter 2016 Earnings Call
Myriad Genetics Fiscal Third-Quarter 2016 Earnings Call 05/03/2016 Exhibit 99.2
Slide 2: Forward Looking Statements
Forward Looking Statements Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or res
Slide 3: Third Quarter Results Exceed Expectations
Third Quarter Results Exceed Expectations Q3FY16 Actual Results YoY Growth Revenue $190.5M 6% Adjusted EPS $0.41 3% GAAP EPS $0.44 27%
Slide 4: Hereditary Cancer Revenue Remains Stable
Hereditary Cancer Revenue Remains Stable Hereditary Cancer Revenue ($ in mil.)
Slide 5: Expanding Advantage in Variant Classification
Expanding Advantage in Variant Classification Number of Variants Pheno™ MuCo™ 3D Structural Analysis LitVIEW™ inSITE™
Slide 6: Updated NCCN Treatment Recommendations
Updated NCCN Treatment Recommendations Genes Change in NCCN Treatment Recommendations PALB2 Consider a prophylactic mastectomy for patients with deleterious mutations BRIP1, RAD51C, RAD51D Consider a prophylactic oophorectomy for patients with deleterious mutations
Slide 7: Mutation Rates Support Testing Patients Under Current Guidelines
Mutation Rates Support Testing Patients Under 60 Current Guidelines Rate of Deleterious Mutations Mutation Rate Unchanged
Slide 8: Hereditary Cancer Market Expansion Progress
Hereditary Cancer Market Expansion Progress Indication Added Market Potential Guidelines Contracting Colon Cancer @ 5% Mutation Risk +$100M 50% All Endometrial Cancer +$150M 50% Breast Cancer <60 yrs +$150M FY17 FY18 All Pancreatic Cancer +$125M Partial FY17 Prostate Cancer +50M FY17 Colon Cancer As
Slide 9: New Product Pipeline Market Opportunity
New Product Pipeline Market Opportunity Currently Reimbursed Market Opportunity Total Market Opportunity (in billions) > $1B Reimbursed TAM
Slide 10: Vectra DA Volumes Grow 18% Year-Over-Year
Vectra DA Volumes Grow 18% Year-Over-Year 18% YoY Volume Growth 17% YoY Revenue Growth Volume in 000’s Revenue Volume in 000’s Revenue in Millions 36,000 tests $10.5 mil. 42,500 tests $12.3 mil.
Slide 11: First Two Private Payer Contracts for Vectra DA
First Two Private Payer Contracts for Vectra DA Medicare Commercial Insurers Signed first two commercial payer contracts representing two million lives 1.5 million RA patients
Slide 12: Prolaris Volumes Grow 90% Year-Over-Year
Prolaris Volumes Grow 90% Year-Over-Year 90% YoY Volume Growth Volume Revenue Prolaris Volume Revenue in Millions *Excludes Medicare retrospective claim revenue 2,250 tests 4,300 tests
Slide 13: Significant Private Payer Progress With Prolaris
Significant Private Payer Progress With Prolaris Commercial Insurers 28 million commercial lives under coverage 200,000 localized prostate cancer patients Medicare Favorable Intermediate
Slide 14: Prolaris and myPlan Renal Cancer Predict Most Important Clinical Endpoints
Prolaris and myPlan Renal Cancer Predict Most Important Clinical Endpoints 3x Risk 8x Risk 8x Risk Study of 440 cancer patients with Gleason score ≤6 Study of 262 renal carcinoma patients 2.2% 6.5% 5.3% 41.0% 2.0% 16.9%
Slide 15: Completing myPath Melanoma Reimbursement Dossier
Completing myPath Melanoma Reimbursement Dossier myPath Melanoma Diagnostic Accuracy myPath Melanoma Diagnostic Accuracy myPath Melanoma Clinical Utility n=437 patients n=736 patients n=218 patients Favorable outcomes study to be presented
Slide 16: Complete Suite of Companion Dx for PARP Inhibitors
Complete Suite of Companion Dx for PARP Inhibitors Tumor Panel Immune Pathway Sample Blood Tumor Tumor Tumor Tumor Biomarkers BRCA1&2 Tumor BRCA1&2 Genome-wide assessment of DNA scar associated with DNA repair defects 80+ clinically actionable oncology genes identified by pharma partners Pathway tes
Slide 17: myPath BiPolar Validation Study Enrollment Starting
myPath BiPolar Validation Study Enrollment Starting Multimarket proteomic assay run on Myriad-RBM Luminex platform Consists of 18 protein analytes from blood Discovery completed in 150 well- characterized BD1 and MDD samples Beginning enrollment in prospective validation study at three major medical
Slide 18: International Revenue Improved to 5% of Total Sales
International Revenue Improved to 5% of Total Sales International Product Revenue as a Percentage of Total Revenue Goal to have international product revenue comprise 10% of sales by FY20
Slide 19: Progress on EndoPredict Reimbursement
Progress on EndoPredict Reimbursement Material increase in reimbursed total addressable market outside the U.S. over the next two years Reimbursed Total Addressable Market
Slide 20: Fiscal Third-Quarter 2016 Revenue By Product
Fiscal Third-Quarter 2016 Revenue By Product Product 3Q16 3Q15 YoY Growth Hereditary Cancer $156.3 $159.0 (2%) Vectra DA $12.3 $10.5 17% Prolaris $5.2 $0.5 940% Other $3.6 $3.0 20% Total Molecular Diagnostic Revenue $177.4 $173.0 3% Pharmaceutical & Clinical Services $13.1 $7.0 87% Total Revenue $19
Slide 21: Fiscal Third-Quarter Financial Results
Fiscal Third-Quarter Financial Results 3Q16 3Q15 YoY Growth Total Revenue $190.5 $180.0 6% Gross Profit $150.3 $143.7 5% Gross Margin 78.9% 79.8% NA Operating Income $42.6 $35.7 19% Adjusted Operating Income $45.8 $46.3 (1%) Adjusted Operating Margin 24.0% 25.7% NA Net Income $32.6 $21.4 52% Diluted
Slide 22: 4Q16 and FY16 Financial Guidance
4Q16 and FY16 Financial Guidance Metric Fiscal Fourth-Quarter 2016 Fiscal Year 2016 Revenue $186 to $188 million $753 to $755 million Diluted EPS $0.32 to $0.34 $1.48 to $1.50 Adjusted EPS $0.36 to $0.38 $1.63 to $1.65